Global Subcutaneous Infusion Devices Market Overview:
A subcutaneous injection is given as a bolus into the subcutis, the layer of skin directly beneath the dermis and epidermis, also known as the cutis. A hypodermic needle and a syringe are typically used. Subcutaneous injections are an excellent way to administer medications such as insulin, morphine, diacetylmorphine, and goserelin. SC, SQ, subcu, sub-Q, SubQ, or subcut are all abbreviations for subcutaneous administration. Subcut is the preferred abbreviation to reduce the possibility of misunderstanding and errors. Because subcutaneous tissue has few blood vessels, drugs injected here are designed for slow, sustained absorption, often with some depot effect. It is slower than intramuscular injections but faster than intradermal injections when compared to other routes of administration. As per latest study released by AMA Research, the Global Subcutaneous Infusion Devices market is expected to see growth rate of 10.5%
|Unit||Value (USD Billion)|
|Customization Scope||Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility|
- The Rising Healthcare Expenditure Related to Diabetes and Favourable Reimbursement Policies for Insulin Pumps are Driving the Growth of the Continuous Subcutaneous Infusion Devices Market.
- The lack Of Approved Product In The Subcutaneous Infusion Delivery Device Market Is Restraints In This Market.
- The Increasing Penetration of the Smart Insulin Pump Has Brought Major Opportunities to the Market.
- The Less Blood Flow through Subcutaneous Infusion Delivery Devices Results in Slow Absorption of Drugs.
Market players are focusing on providing Subcutaneous Infusion Devices with higher quality along with complying with all regulatory standards to fascinate more end users. They are also focusing on the introduction of numerous advanced & attractive features to further offer qualified Subcutaneous Infusion Devices. Besides, the numerous industry profitability has led to the entry of new players, in turn, increasing the level of rivalry in the already competitive market.
Some of the key players profiled in the report are Gerresheimer AG (Germany), Medtronic Plc (Ireland), Ypsomed AG (Switzerland), Elcam Medical Group (Israel), Novo Nordisk (Denmark), Insulet Corporation (United States), Becton, Dickinson and Company (United States), West Pharmaceutical Services, Inc. (United States), PharmaJet (United States) and Unilife Corporation (United States). Additionally, following companies can also be profiled that are part of our coverage like Inolife Sciences (Canada), Cellnovo (United Kingdom), Owen Mumford (United Kingdom), Roche (Switzerland), Mitsubishi Tanabe Pharma (Neuroderm) (Japan), Supernus (United States) and AbbVie (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Subcutaneous Infusion Devices market by 2027. Considering Market by Usage, the sub-segment i.e. Disposable will boost the Subcutaneous Infusion Devices market. Considering Market by End Use, the sub-segment i.e. Diabetes will boost the Subcutaneous Infusion Devices market.
Latest Market Insights:
In November 2021, Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector. The go-to-market approach for the autoinjector combines the complementary strengths of both companies - Gerresheimer as a solution provider for medical devices and primary packaging solutions and Midas Pharma as experienced facilitator for global pharma projects and provider of products and services along the pharmaceutical value chain.
In December 2021, Gerresheimer has entered into an important agreement involving its Advanced Technologies division. An established US biotech company will rely on Gerresheimer's innovative strength and engineering expertise for the development of a new pump to deliver a leading drug for the treatment of rare diseases via continuous parenteral administration.
Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a device that has been found substantially equivalent to such a device, has an approval under section 515 of the act FDA must promulgate a regulation under section 515(b) of the act requiring such approval, except as provided in paragraph (b) of this section. Such a regulation under section 515(b) of the act shall not be effective during the grace period ending on the 90th day after its promulgation or on the last day of the 30th full calendar month after the regulation that classifies the device into class III is effective, whichever is later.
What Can be Explored with the Subcutaneous Infusion Devices Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Subcutaneous Infusion Devices Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Subcutaneous Infusion Devices
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Subcutaneous Infusion Devices market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Subcutaneous Infusion Devices market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceutical companies, Medical instruments Manufacturers, Hospitals and Healthcare facilities, New Entrants and Investors, Legalized Cannabis Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.